Antithrombotic Effect of the Ethanol Extract of Angelica gigas Nakai (AGE 232)
| Autor: | Joo-Won Suh, Hui Jin, Hyunwoo Park, Min Sang Kim, Pia Loreto Werlinger Bravo, Hanki Lee, Hirofumi Matsui |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
side effect
Side effect Science Pharmacology Article General Biochemistry Genetics and Molecular Biology Umbilical vein anti-platelet aggregation chemistry.chemical_compound Antithrombotic Paralysis Medicine cardiovascular diseases Thrombus improvement of blood circulation Stroke Ecology Evolution Behavior and Systematics Ethanol thrombus formation Angelica gigas Nakai biology business.industry Paleontology acetylsalicylic acid medicine.disease biology.organism_classification Angelica gigas chemistry Space and Planetary Science cardiovascular system medicine.symptom business bleeding in the gut |
| Zdroj: | Life, Vol 11, Iss 939, p 939 (2021) Life Volume 11 Issue 9 |
| ISSN: | 2075-1729 |
| Popis: | Cardiovascular diseases, such as stroke, are the most common causes of death in developed countries. Ischemic stroke accounts for 85% of the total cases and is caused by abnormal thrombus formation in the vessels, causing deficient blood and oxygen supply to the brain. Prophylactic treatments include the prevention of thrombus formation, of which the most used is acetylsalicylic acid (ASA) however, it is associated with a high incidence of side effects. Angelica gigas Nakai (AG) is a natural herb used to improve blood circulation via anti-platelet aggregation, one of the key processes involved in thrombus formation. We examined the antithrombotic effects of AGE 232, the ethanol extract of A. gigas Nakai. AGE 232 showed a significant reduction in death or paralysis in mice caused by collagen/epinephrine-induced thromboembolism in a dose-dependent manner and inhibition of collagen-induced human platelet aggregation in a concentration-dependent manner. Additionally, AGE 232-treated mice did not show severe bleeding in the gut compared to ASA-treated mice. AGE 232 resulted in a decrease in the number of neutrophils attached to the human umbilical vein endothelial cells (HUVECs) and lower inhibition of COX-1 in response to bleeding and damage to blood vessels, a major side effect of ASA. Therefore, AGE 232 can prevent thrombus formation and stroke. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|